HK1246656A1 - 含有伊立替康的口服固體製劑及其製備方法 - Google Patents

含有伊立替康的口服固體製劑及其製備方法

Info

Publication number
HK1246656A1
HK1246656A1 HK18106185.2A HK18106185A HK1246656A1 HK 1246656 A1 HK1246656 A1 HK 1246656A1 HK 18106185 A HK18106185 A HK 18106185A HK 1246656 A1 HK1246656 A1 HK 1246656A1
Authority
HK
Hong Kong
Prior art keywords
preparing
same
formulation containing
solid formulation
oral solid
Prior art date
Application number
HK18106185.2A
Other languages
English (en)
Inventor
朴炯玟(凱勒)
鄭名棋
金唇哲
金用鎰
朴宰賢
禹鍾守
Original Assignee
韓美藥品株式會社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 韓美藥品株式會社 filed Critical 韓美藥品株式會社
Publication of HK1246656A1 publication Critical patent/HK1246656A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
HK18106185.2A 2015-06-30 2018-05-11 含有伊立替康的口服固體製劑及其製備方法 HK1246656A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150093413A KR102293907B1 (ko) 2015-06-30 2015-06-30 이리노테칸 함유 경구용 고형제제 및 그 제조방법
PCT/KR2016/006513 WO2017003120A1 (en) 2015-06-30 2016-06-20 Oral solid formulation containing irinotecan and method of preparing the same

Publications (1)

Publication Number Publication Date
HK1246656A1 true HK1246656A1 (zh) 2018-09-14

Family

ID=57608859

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18106185.2A HK1246656A1 (zh) 2015-06-30 2018-05-11 含有伊立替康的口服固體製劑及其製備方法

Country Status (32)

Country Link
US (2) US11090299B2 (zh)
EP (1) EP3300483B1 (zh)
JP (2) JP6835746B2 (zh)
KR (2) KR102293907B1 (zh)
CN (1) CN107949375B (zh)
AR (1) AR105203A1 (zh)
AU (2) AU2016286804B2 (zh)
BR (1) BR112017028468B1 (zh)
CA (1) CA2988079C (zh)
CL (1) CL2017003437A1 (zh)
CO (1) CO2017013317A2 (zh)
CR (1) CR20170604A (zh)
DO (1) DOP2017000307A (zh)
EC (1) ECSP17085443A (zh)
ES (1) ES2930663T3 (zh)
GT (1) GT201700280A (zh)
HK (1) HK1246656A1 (zh)
IL (1) IL256278B (zh)
JO (1) JO3683B1 (zh)
MX (2) MX2017014994A (zh)
MY (1) MY191297A (zh)
NZ (1) NZ737238A (zh)
PE (1) PE20181040A1 (zh)
PH (1) PH12017502376B1 (zh)
RU (1) RU2716595C2 (zh)
SA (1) SA517390602B1 (zh)
SG (1) SG10201913274VA (zh)
SV (1) SV2017005603A (zh)
TW (2) TWI750125B (zh)
UY (1) UY36761A (zh)
WO (1) WO2017003120A1 (zh)
ZA (1) ZA201708429B (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102293907B1 (ko) * 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물
KR102185475B1 (ko) * 2019-06-20 2020-12-02 대화제약 주식회사 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물
KR102444073B1 (ko) * 2020-01-06 2022-09-16 (주)휴온스 안정성이 향상된 메틸에르고메트린말레산염 함유 약제학적 제제 및 이의 제조방법
KR20220006776A (ko) * 2020-07-09 2022-01-18 주식회사유한양행 다이아미노피리미딘 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물 및 이의 제조방법
WO2022031099A1 (ko) * 2020-08-06 2022-02-10 에스케이바이오팜 주식회사 카바메이트 화합물을 포함하는 경구용 고형 제제 및 이의 제조방법
CA3194694A1 (en) 2020-10-07 2022-04-14 Sameer Urgaonkar Acetamido-phenyltetrazole derivatives and methods of using the same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
CA2300892A1 (en) 1998-06-18 1999-12-23 The George Washington University Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects
GB9925127D0 (en) 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
JP2002154963A (ja) * 2000-11-14 2002-05-28 Yakult Honsha Co Ltd 徐放性抗腫瘍剤
US6476068B1 (en) * 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
EP1487840B1 (en) * 2002-03-01 2007-06-13 Pfizer Italia S.r.l. Crystalline polymorphic form of irinotecan hydrochloride
US20060030578A1 (en) 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
JP4245384B2 (ja) * 2003-03-18 2009-03-25 株式会社ヤクルト本社 カンプトテシン類含有医薬組成物
US20050208146A1 (en) * 2003-10-30 2005-09-22 Pfizer Inc Novel dosage and administration method for oral camptosar
ES2534853T3 (es) * 2004-10-01 2015-04-29 Kabushiki Kaisha Yakult Honsha Sal de adición de ácido de irinotecán
AU2005311652B2 (en) 2004-12-03 2010-12-02 Merck Sharp & Dohme Corp. Pharmaceutical formulation of carboxamide HIV integrase inhibitors containing a release rate controlling composition
BRPI0611375A2 (pt) 2005-05-23 2010-08-31 Novartis Ag formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona
CN101283983A (zh) * 2007-10-26 2008-10-15 南京长澳医药科技有限公司 一种稳定的喜树碱类药物脂质体组合物
US7880591B2 (en) 2008-02-01 2011-02-01 Apple Inc. Consumer abuse detection system and method
EP2153821A1 (en) 2008-08-06 2010-02-17 BioAlliance Pharma Oral formulations of camptothecin derivatives
CN102617584B (zh) * 2012-03-14 2013-10-16 海南锦瑞制药股份有限公司 一种盐酸伊立替康化合物及其药物组合物
PE20151024A1 (es) 2012-11-30 2015-07-27 Glaxosmithkline Llc Composicion farmaceutica novedosa
EP3094635B1 (en) * 2014-01-17 2018-07-04 Oncoral Pharma ApS Solid oral dosage form of irinotecan for the treatment of cancer
KR102293907B1 (ko) * 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법

Also Published As

Publication number Publication date
PH12017502376A1 (en) 2018-06-25
CL2017003437A1 (es) 2018-06-22
DOP2017000307A (es) 2018-03-15
US20180153878A1 (en) 2018-06-07
JP2021070705A (ja) 2021-05-06
AU2016286804A1 (en) 2017-11-30
ZA201708429B (en) 2019-06-26
PE20181040A1 (es) 2018-07-03
MY191297A (en) 2022-06-14
CN107949375A (zh) 2018-04-20
IL256278B (en) 2020-11-30
SA517390602B1 (ar) 2022-11-09
IL256278A (en) 2018-02-28
CA2988079C (en) 2023-09-26
CA2988079A1 (en) 2017-01-05
TWI750125B (zh) 2021-12-21
WO2017003120A1 (en) 2017-01-05
RU2017143849A (ru) 2019-08-01
BR112017028468A2 (pt) 2018-08-28
ECSP17085443A (es) 2018-01-31
GT201700280A (es) 2019-10-10
KR102293907B1 (ko) 2021-08-26
JO3683B1 (ar) 2020-08-27
KR20170003143A (ko) 2017-01-09
TW202137985A (zh) 2021-10-16
PH12017502376B1 (en) 2018-06-25
AU2021204259A1 (en) 2021-07-22
KR20210106946A (ko) 2021-08-31
JP2018519279A (ja) 2018-07-19
ES2930663T3 (es) 2022-12-20
TW201713339A (zh) 2017-04-16
US20210330666A1 (en) 2021-10-28
KR102317664B1 (ko) 2021-10-26
SG10201913274VA (en) 2020-03-30
NZ737238A (en) 2024-03-22
US11090299B2 (en) 2021-08-17
EP3300483B1 (en) 2022-11-09
AR105203A1 (es) 2017-09-13
EP3300483A4 (en) 2018-12-12
MX2017014994A (es) 2018-08-15
JP6835746B2 (ja) 2021-02-24
MX2021004439A (es) 2021-05-27
CN107949375B (zh) 2023-04-21
EP3300483A1 (en) 2018-04-04
SV2017005603A (es) 2018-03-12
UY36761A (es) 2016-12-30
CR20170604A (es) 2018-04-27
AU2016286804B2 (en) 2021-03-25
RU2716595C2 (ru) 2020-03-13
CO2017013317A2 (es) 2018-03-28
RU2017143849A3 (zh) 2019-09-25
BR112017028468B1 (pt) 2023-03-28

Similar Documents

Publication Publication Date Title
IL250744A0 (en) A method for preparing flavociclib and its pharmaceutical preparations
HK1252030A1 (zh) 葡萄糖激酶激活劑的口服製劑及其製備方法
HK1246656A1 (zh) 含有伊立替康的口服固體製劑及其製備方法
HK1254055A1 (zh) 製備奧貝膽酸及其衍生物的方法
ZA202104969B (en) Compositions comprising 15-hepe and methods of using the same
PL3373910T3 (pl) Preparat echinomycyny, sposób wytwarzania i sposób stosowania
IL266345A (en) Dihydropyrimidine compound and method of preparation and use thereof
IL258139A (en) Nicotine compositions and methods for their preparation and use
IL266132A (en) Pharmacological formulations and methods for their preparation
IL262405A (en) Methods for the preparation of obeticholic acid and derivatives thereof
HK1247136A1 (zh) 包含15-hepe的組合物和其使用方法
ZA201801015B (en) Oral care compositions and methods of using the compositions
HK1214767A1 (zh) 片劑形式的藥物組合物及其製造方法
HUE044804T2 (hu) Citizint tartalmazó szilárd gyógyszerkészítmény és eljárás elõállítására
HK1248527A1 (zh) 牙科組合物和使用方法
IL258304B (en) Oral treatment compounds and methods of using the compounds
IL254597A0 (en) Crystalline form of ahu377, method for its preparation and use
HK1232209A1 (zh) 製備 -乙酰氧基丙酸及其衍生物的方法
RS61955B1 (sr) Farmaceutska kompozicija koja sadrži darunavir i postupak za njegovo dobijanje
ZA201508930B (en) Pharmaceutical composition comprising darunavir and method for the preparation thereof
GB201511863D0 (en) Pharmaceutical compositions comprising hexaminolevulnic acid and methods of using the same